Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD1 | Q13393 | 1/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.51 |
| ▸ | BPTF | Q12830 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29844434 | 1.00 | PLD1 (0.86) | PLD1ALDH1A1HSD17B10CYP3A4HPGD | |
| SCHEMBL7900 | 0.93 | PLD1 (1.00) | PLD1ALDH1A1HSD17B10CYP3A4HPGD | |
| SCHEMBL893565 | 0.93 | PLD1 (1.00) | PLD1ALDH1A1HSD17B10CYP3A4HPGD | |
| SCHEMBL29400889 | 0.93 | PLD1 (1.00) | PLD1ALDH1A1HSD17B10CYP3A4HPGD | |
| Hydrochloric Acid SCHEMBL27481639 | 0.91 | PLD1 (0.96) | PLD1ALDH1A1HSD17B10CYP3A4HPGD | |
| Piperazine SCHEMBL27920772 | 0.91 | PLD1 (0.96) | PLD1ALDH1A1HSD17B10CYP3A4HPGD | |
| Hydrochloric Acid SCHEMBL6349557 | 0.91 | PLD1 (0.96) | PLD1ALDH1A1HSD17B10CYP3A4HPGD | |
| Ammonia Solution, Strong SCHEMBL17926100 | 0.91 | PLD1 (0.96) | PLD1ALDH1A1HSD17B10CYP3A4HPGD | |
| Hydrochloric Acid SCHEMBL4165242 | 0.91 | PLD1 (0.96) | PLD1ALDH1A1HSD17B10CYP3A4HPGD | |
| Bromide SCHEMBL11807389 | 0.91 | PLD1 (0.96) | PLD1ALDH1A1HSD17B10CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115093794-B | Polysilicon polishing composition and application thereof | 万华化学集团电子材料有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-115093794-A | Polysilicon polishing composition and application thereof | 万华化学集团电子材料有限公司 | 2022-09-23 | — | — | CN | claimed |
| EP-4321504-B1 | PEGYLATED LIPID AND LIPOSOME MODIFIED THEREBY, AND PHARMACEUTICAL COMPOSITION COMPRISING LIPOSOME AND PREPARATION AND USE THEREOF | XIAMEN SINOPEG BIOTECH CO LTD (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20250288531-A1 | AMINO ACID-BASED CATIONIC LIPID CONTAINING UNSATURATED BONDS | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| EP-4534525-A1 | AMINO ACID-BASED CATIONIC LIPID CONTAINING UNSATURATED BONDS | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2025-04-09 | — | — | EP | disclosed |
| US-20240197633-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| US-20240199555-A1 | APPLICATIONS OF BIASED LIGANDS OF THE SEROTONIN 5-HT7 RECEPTOR FOR THE TREATMENT OF PAIN, MULTIPLE SCLEROSIS AND THE CONTROL OF THERMOREGULATION | Université d'Orléans (FR) | 2024-06-20 | — | — | US | disclosed |
| US-12006301-B1 | And synthesis of dual 5-HT1A and 5-HT7 receptor ligands | FLORIDA A&M UNIVERSITY (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240180951-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2024-06-06 | — | — | US | disclosed |
| EP-4321504-A1 | PEGYLATED LIPID AND LIPOSOME MODIFIED THEREBY, AND PHARMACEUTICAL COMPOSITION COMPRISING LIPOSOME AND PREPARATION AND USE THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2024-02-14 | — | — | EP | disclosed |
| EP-4321503-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED THEREBY, PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME, PREPARATION THEREOF, AND USE THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2024-02-14 | — | — | EP | disclosed |
| EP-1419150-A2 | PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2004-05-19 | — | — | EP | disclosed |
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040002488-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | WEINSTOCK, STEVEN F. | 2004-01-01 | — | — | US | disclosed |
| WO-2003008407-A2 | PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-SYNTHELABO (FR) | 2003-01-30 | — | — | WO | disclosed |
| EP-1243268-A1 | MEDICINAL COMPOSITION | Nippon Shinyaku Co., Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-20020045618-A1 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | US | disclosed |
| EP-1175416-A1 | HETEROARYL DIAZACYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-01-30 | — | — | EP | disclosed |
| EP-1156045-A1 | AMIDE DERIVATIVES AND DRUG COMPOSITIONS | Nippon Shinyaku Co., Ltd. (JP) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000064885-A1 | HETEROARYL DIAZACYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180951-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | LIPG, PHOSPHO1, LDLR | PLD1 538/4885ALDH1A1 4614/4885HSD17B10 3074/4885 |
| US-20020045618-A1 | Heteroaryl diazacycloalkanes, their preparation and use | CHRNA5, CHRNA7, CHRNA3 | PLD1 1690/4885ALDH1A1 1310/4885HSD17B10 600/4885 |
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, HSD17B11 | PLD1 3391/4885ALDH1A1 246/4885HSD17B10 141/4885 |
| US-12006301-B1 | And synthesis of dual 5-HT1A and 5-HT7 receptor ligands | HTR7, HTR1A, HTR5A | PLD1 1228/4885ALDH1A1 1779/4885HSD17B10 2315/4885 |
| US-20240197633-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | LIPG, LDLR, LIPA | PLD1 565/4885ALDH1A1 4449/4885HSD17B10 3334/4885 |
| US-20040002488-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, HSD17B11 | PLD1 3391/4885ALDH1A1 246/4885HSD17B10 141/4885 |
| US-20250288531-A1 | AMINO ACID-BASED CATIONIC LIPID CONTAINING UNSATURATED BONDS | SLC7A1, LNPEP, SLC1A5 | PLD1 380/4885ALDH1A1 2947/4885HSD17B10 2045/4885 |
| US-20240199555-A1 | APPLICATIONS OF BIASED LIGANDS OF THE SEROTONIN 5-HT7 RECEPTOR FOR THE TREATMENT OF PAIN, MULTIPLE SCLEROSIS AND THE CONTROL OF THERMOREGULATION | HTR7, HTR1A, CNR1 | PLD1 2174/4885ALDH1A1 1323/4885HSD17B10 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.